RBC Sees Weak Merck Data As Positive For Gilead By: Benzinga via Benzinga November 10, 2014 at 09:29 AM EST In a note from RBC Capital analyst Michael Yee, Merck & Co., Inc.'s (NYSE: MRK) weaker-than-expected data for hepatitis C is ... Read More >> Related Stocks: Gilead Sciences Merck & Co